Uncategorized
Ocular Therapeutix™ Announces Encouraging Top-Line Results from Exploratory Phase 2 Trial for DEXTENZA™ in Patients with Inflammatory Dry Eye Disease
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from a Phase 2 exploratory clinical trial designed to evaluate a range of objective and subjective measures (signs and symptoms, respectively) for DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot for the treatment of inflammatory dry
